MS Clinical Trials in Connecticut

19 active trials · 12 recruiting

19 active multiple sclerosis clinical trials have at least one study site in Connecticut, 12 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 8 MS treatment centers in Connecticut; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in Connecticut

RecruitingPhase 1

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

RO7121932 IV · RO7121932 SC

5 states129 participantsDetails ›

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor: Amgen

Ocrelizumab (US) · Ocrelizumab (EU)

17 states444 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Ocrelizumab · Placebo for Ocrelizumab

9 states123 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

CC-97540 · Fludarabine

14 states120 participantsDetails ›

Recruiting

Identifying and Characterizing Preclinical MS

Sponsor: Yale University

biological samples

1 state1000 participantsDetails ›

RecruitingPhase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Sponsor: Tiziana Life Sciences LTD

Foralumab · Placebo

5 states54 participantsDetails ›

RecruitingPhase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Sponsor: Yale University

[ 18F]3F4AP · [18F]MK6240

1 state105 participantsDetails ›

Recruiting

Intestinal Immunity in Neurologic Disease

Sponsor: Yale University

Colon Tissue Biopsy

1 state100 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

23 states1011 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 3

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

13 states751 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patients

Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

Sponsor: The Cleveland Clinic

MRI

9 states420 participantsDetails ›

Closed to new patients

Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

Sponsor: Yale University

COVID19 vaccine

1 state400 participantsDetails ›

Closed to new patientsPhase 1

Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis

Sponsor: Griffin Hospital

Fecal microbial transplant (FMT)

1 state9 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Get it on Google Play